Company Implements Plan to Reduce Operating Costs;

         Expected Cash Spend for Q32013 Lower than Previous Guidance

New York, NY  - October 4,  2013 -  Delcath Systems, Inc.  (NASDAQ: DCTH),  a 
specialty pharmaceutical  and  medical  device company  focused  on  oncology, 
announced  today  that  as   part  of  its   efforts  to  increase   operating 
efficiencies, the Company has completed a strategic reorganization under which
it has eliminated 21 positions, or approximately 33% of its global  workforce. 
The Company expects this reorganization, in conjunction with other cost saving
measures, to significantly lower cash utilization.

For its fiscal third quarter 2013, the Company expects cash utilization to  be 
between $7.0-8.0 million, as  compared to its  previous guidance of  $9.0-10.0 
million for  the period.  For  its fiscal  fourth  quarter 2013,  the  Company 
currently expects cash  utilization to  be at the  lower end  of its  previous 
guidance of $6.0-8.0  million. Additionally,  as a result  of the  initiatives 
implemented over the past  three weeks, the Company  expects to reduce  annual 
operating costs by approximately $10 million. The Company believes that  these 
actions will help  preserve the  Company's ability to  initiate the  strategic 
objectives currently under  evaluation. Most  of the savings  are expected  to 
come from marketing, administrative expenses and research and development.  As 
of September, 30  2013, the  Company estimates  cash and  cash equivalents  of 
approximately $28 million.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on  oncology. Our  proprietary  drug/device combination  product,  the 
Delcath  Hepatic  Delivery  System,  is  designed  to  administer  high   dose 
chemotherapy and other therapeutic agents to the liver, while controlling  the 
systemic exposure  of those  agents. The  Company's initial  focus is  on  the 
treatment of  primary and  metastatic  liver cancers.  Outside of  the  United 
States, our proprietary product to deliver and filter melphalan  hydrochloride 
is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for
melphalan hydrochloride. The Company obtained authorization to affix a CE Mark
for the Generation Two CHEMOSAT Delivery  System for Melphalan in April  2012. 
The right to  affix the  CE mark  allows the Company  to market  and sell  the 
CHEMOSAT Delivery System for Melphalan in Europe. In addition, the Company has
initiated plans to investigate the  Melphalan Hydrochloride for Injection  for 
use with the  Delcath Hepatic Delivery  System for primary  liver cancer.  For 
more information, please visit the Company's website at

Private Securities Litigation Reform  Act of 1995 provides  a safe harbor  for 
forward-looking statements made  by the Company  or on its  behalf. This  news 
release contains  forward-looking statements,  which  are subject  to  certain 
risks and uncertainties  that can  cause actual results  to differ  materially 
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to: efficiencies and reduction in  cash 
utilization achieved through September 2013 staff reductions, the  leadership 
transition plan  and its  impact on  the Company,  the Company's  ability  to 
satisfy the requirements of the  FDA's Complete Response Letter and  provide 
the same in a  timely manner, clinical adoption,  use and resulting sales,  if 
any, for the CHEMOSAT  system to deliver and  filter melphalan in Europe,  our 
ability to  successfully  commercialize  the chemosaturation  system  and  the 
potential of  the chemosaturation  system  as a  treatment for  patients  with 
primary  and  metastatic  disease  in   the  liver,  our  ability  to   obtain 
reimbursement for  the CHEMOSAT  system  in various  markets, the  timing  and 
results of future clinical trials including without limitation the HCC trials,
approval of  the current  or future  chemosaturation system  for delivery  and 
filtration of  melphalan, doxorubicin  or  other chemotherapeutic  agents  for 
various indications in the US and/or in foreign markets, actions by the FDA or
other foreign  regulatory agencies,  our ability  to successfully  enter  into 
strategic  partnership  and  distribution  arrangements  in  foreign   markets 
including Australia and key Asian markets  and timing and revenue, if any,  of 
the same, uncertainties  relating to the  timing and results  of research  and 
development projects,,  and  uncertainties  regarding our  ability  to  obtain 
financial and other resources for  any research, development, clinical  trials 
and commercialization  activities. These  factors, and  others, are  discussed 
from time to time in our filings with the Securities and Exchange  Commission. 
You should not place undue reliance on these forward-looking statements, which
speak only  as of  the  date they  are made.  We  undertake no  obligation  to 
publicly update or revise these  forward-looking statements to reflect  events 
or circumstances after the date they are made.

Investor Contact:                Media Contact:
Michael Polyviou/Patty Eisenhaur John Carter
EVC Group                        EVC Group
212-850-6020/951-316-0577        212-850-6021


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.